文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症患者高蛋白与标准蛋白供给对功能恢复的影响(PRECISe):研究者发起的双盲多中心平行组随机对照试验

Effect of high versus standard protein provision on functional recovery in people with critical illness (PRECISe): an investigator-initiated, double-blinded, multicentre, parallel-group, randomised controlled trial in Belgium and the Netherlands.
PubMed 文献 · Lancet · 2024-01-01
一句话结论在机械通气重症患者中,高蛋白肠内供给(2.0 g/kg/天)较标准蛋白(1.3 g/kg/天)180天内EQ-5D-5L健康效用评分更低(均值差-0.05),未改善功能结局。

PRECISe试验为研究者发起的双盲、多中心、平行组随机对照试验,在5家荷兰医院和5家比利时医院纳入ICU入住24小时内启动有创机械通气且预期有创通气≥3天的重症患者,排除肠内营养禁忌、濒死状态、BMI<18 kg/m²、无透析指征的肾衰竭或肝性脑病者。患者随机接受等热量肠内喂养,标准蛋白组为1.3 kcal/mL、0.06 g蛋白/mL,高蛋白组为1.3 kcal/mL、0.10 g蛋白/mL,干预限于ICU需要肠内喂养期间、最长90天。主要终点为随机后30天、90天、180天EQ-5D-5L健康效用评分(校正基线值),高蛋白组低于标准蛋白组,均值差-0.05(95%CI -0.10至-0.01;p=0.031)。高蛋白组胃肠道不耐受症状发生率更高(OR 1.76,95%CI 1.06至2.92;p=0.030),全随访期死亡率两组无显著差异(HR 1.14,95%CI 0.92至1.40;p=0.22)。作者结论认为高蛋白肠内供给未改善功能结局,反而与更差的健康相关生活质量相关。

要点

  • 高蛋白肠内供给(2.0 g/kg/天)较标准蛋白(1.3 g/kg/天)180天内EQ-5D-5L健康效用评分更低:均值差-0.05(95%CI -0.10至-0.01;p=0.031)。
  • 高蛋白组胃肠道不耐受症状发生率更高:OR 1.76(95%CI 1.06至2.92;p=0.030)。
  • 全随访期死亡率标准蛋白组0.38(SE 0.02) vs 高蛋白组0.42(SE 0.02),HR 1.14(95%CI 0.92至1.40;p=0.22),无显著差异。
  • 纳入标准为ICU入住24小时内启动有创机械通气且预期有创通气≥3天;排除肠内营养禁忌、濒死状态、BMI<18 kg/m²、无透析指征的肾衰竭或肝性脑病。
  • 作者结论:高蛋白肠内供给未改善功能结局,反而与更差的健康相关生活质量相关。

适用人群与场景

  • 纳入:ICU入住24小时内启动有创机械通气且预期有创通气持续时间≥3天的重症成人患者。
  • 排除:肠内营养禁忌、濒死状态、BMI<18 kg/m²、无透析指征的肾衰竭或肝性脑病。
  • 场景:5家荷兰医院和5家比利时医院的ICU;干预限于ICU需要肠内喂养期间,最长90天。

处置流程与药物剂量

  • 标准蛋白组:等热量肠内喂养,1.3 kcal/mL、0.06 g蛋白/mL(即标准蛋白1.3 g/kg/天)。
  • 高蛋白组:等热量肠内喂养,1.3 kcal/mL、0.10 g蛋白/mL(即高蛋白2.0 g/kg/天)。
  • 研究营养干预限于患者ICU停留期间需要肠内喂养的时段,最长90天。

研究设计与关键结果

  • 研究类型:研究者发起的双盲、多中心、平行组随机对照试验,在5家荷兰医院和5家比利时医院进行;935例患者随机,女性335例(35.8%)、男性600例(64.2%);标准蛋白组465例(49.7%),高蛋白组470例(50.3%)。
  • 主要终点评估:标准蛋白组430/465例(92.5%)、高蛋白组419/470例(89.1%)完成主要终点评估。
  • 主要终点:随机后180天内(30天、90天、180天评估)EQ-5D-5L健康效用评分,高蛋白组低于标准蛋白组,均值差-0.05(95%CI -0.10至-0.01;p=0.031)。
  • 安全性终点:全随访期死亡概率标准蛋白组0.38(SE 0.02) vs 高蛋白组0.42(SE 0.02),HR 1.14(95%CI 0.92至1.40;p=0.22)。
  • 不良事件:高蛋白组胃肠道不耐受症状发生率更高,OR 1.76(95%CI 1.06至2.92;p=0.030);其他不良事件发生率两组无差异。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,对机械通气的重症患者,高蛋白肠内供给(2.0 g/kg/天)较标准蛋白(1.3 g/kg/天)未改善180天内功能结局,且与更差的健康相关生活质量相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Increased protein provision might ameliorate muscle wasting and improve long-term outcomes in critically ill patients. The aim of the PRECISe trial was to assess whether higher enteral protein provision (ie, 2·0 g/kg per day) would improve health-related quality of life and functional outcomes in critically ill patients who were mechanically ventilated compared with standard enteral protein provision (ie, 1·3 g/kg per day).

METHODS: The PRECISe trial was an investigator-initiated, double-blinded, multicentre, parallel-group, randomised controlled trial in five Dutch hospitals and five Belgian hospitals. Inclusion criteria were initiation of invasive mechanical ventilation within 24 h of intensive care unit (ICU) admission and an expected duration of invasive ventilation of 3 days or longer. Exclusion criteria were contraindications for enteral nutrition, moribund condition, BMI less than 18 kg/m2, kidney failure with a no dialysis code, or hepatic encephalopathy. Patients were randomly assigned to one of four randomisation labels, corresponding with two study groups (ie, standard or high protein; two labels per group) in a 1:1:1:1 ratio through an interactive web-response system. Randomisation was done via random permuted-block randomisation in varying block sizes of eight and 12, stratified by centre. Participants, care providers, investigators, outcome assessors, data analysts, and the independent data safety monitoring board were all blinded to group allocation. Patients received isocaloric enteral feeds that contained 1·3 kcal/mL and 0·06 g of protein/mL (ie, standard protein) or 1·3 kcal/mL and 0·10 g of protein/mL (ie, high protein). The study-nutrition intervention was limited to the time period during the patient's ICU stay in which they required enteral feeding, with a maximum of 90 days. The primary outcome was EuroQoL 5-Dimension 5-level (EQ-5D-5L) health utility score at 30 days, 90 days, and 180 days after randomisation, adjusted for baseline EQ-5D-5L health utility score. This trial was registered with ClinicalTrials.gov (NCT04633421) and is closed to new participants.

FINDINGS: Between Nov 19, 2020, and April 14, 2023, 935 patients were randomly assigned. 335 (35·8%) of 935 patients were female and 600 (64·2%) were male. 465 (49·7%) of 935 were assigned to the standard protein group and 470 (50·3%) were assigned to the high protein group. 430 (92·5%) of 465 patients in the standard protein group and 419 (89·1%) of 470 patients in the high protein group were assessed for the primary outcome. The primary outcome, EQ-5D-5L health utility score during 180 days after randomisation (assessed at 30 days, 90 days, and 180 days), was lower in patients allocated to the high protein group than in those allocated to the standard protein group, with a mean difference of -0·05 (95% CI -0·10 to -0·01; p=0·031). Regarding safety outcomes, the probability of mortality during the entire follow-up was 0·38 (SE 0·02) in the standard protein group and 0·42 (0·02) in the high protein group (hazard ratio 1·14, 95% CI 0·92 to 1·40; p=0·22). There was a higher incidence of symptoms of gastrointestinal intolerance in patients in the high protein group (odds ratio 1·76, 95% CI 1·06 to 2·92; p=0·030). Incidence of other adverse events did not differ between groups.

INTERPRETATION: High enteral protein provision compared with standard enteral protein provision resulted in worse health-related quality of life in critically ill patients and did not improve functional outcomes during 180 days after ICU admission.

FUNDING: Netherlands Organisation for Healthcare Research and Development and Belgian Health Care Knowledge Centre.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Bels JLM, Thiessen S, van Gassel RJJ, et al. Effect of high versus standard protein provision on functional recovery in people with critical illness (PRECISe): an investigator-initiated, double-blinded, multicentre, parallel-group, randomised controlled trial in Belgium and the Netherlands. Lancet. 2024. PMID: 39153816. doi:10.1016/S0140-6736(24)01304-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。